NSE:SPARC

Sun Pharma Advanced Research Company Limited · NSE · Healthcare · INR · FY for 2026

Figures on this page computed 2026-11-08 12:41 UTC

Last close

n/aINR

Market data

4.0xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
INR
- computed
- Computed from the filing for 2026
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
INR
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
82.7%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
INR
- Computed from the filing for 2026
- Computed from the filing for 2026
-15.8%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
INR
- Computed from the filing for 2026
- Computed from the filing for 2026
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
INR
- Computed from the filing for 2026
- Computed from the filing for 2026
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
INR
- computed

5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

5.92x

-29.38x

1.23x

4.32x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2026

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2026

Sales5.92x
Its own average over 10 years, 3.17B.
Profit-29.38x
Its own average over 10 years, -528.7M.
Free cash flow1.23x
Its own average over 10 years, -2.41B.
Debt4.32x
Its own average over 10 years, 1.30B.
Pricen/a
Its own average over 0 years. Market data

Profit is furthest from its own average, at -29.38 times.

Sales is 5.92 times its own 10-year average; Profit is -29.38 times its own 10-year average; Free cash flow is 1.23 times its own 10-year average; Debt is 4.32 times its own 10-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2026

Sales against its own 10-year average5.92
Source
computed
Statement
income
Fiscal year
2026
Reported in
INR
Profit against its own 10-year average-29.38
Source
computed
Statement
income
Fiscal year
2026
Reported in
INR
Free cash flow against its own 10-year average1.23
Source
computed
Statement
income
Fiscal year
2026
Reported in
INR
Debt against its own 10-year average4.32
Source
computed
Statement
income
Fiscal year
2026
Reported in
INR
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
INR